TMDX News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

TM

Mkt Cap

$2.65B

Volume

942.63K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Why Is TransMedics (TMDX) Up 10.2% Since Last Earnings Report?TransMedics (TMDX) reported Q2 2026 earnings that missed estimates by 12%, with EPS down 52.2% year-over-year to $0.44. However, revenues grew 20.7% to $189.9 million, driven by strong service revenue growth of 28.6%. The company raised its 2026 revenue guidance but lowered adjusted operating margin expectations due to accelerated OCS Kidney investments. Analyst estimates have shifted downward by 31.5% since the earnings release, resulting in a Zacks Rank #5 (Strong Sell) rating.Zacks Investment Research · Sep 3, 2026

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDXRosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offers legal representation for affected investors.GlobeNewswire Inc. · Sep 3, 2026

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDXRosen Law Firm is investigating potential breaches of fiduciary duties by directors and officers of TransMedics Group, Inc. The firm is seeking shareholders to join the investigation and offering legal representation for affected investors.GlobeNewswire Inc. · Aug 29, 2026

ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Microvast Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - MVSTRosen Law Firm is encouraging investors who purchased securities of Microvast Holdings (MVST) between April 1, 2025 and March 16, 2026 to join a class action lawsuit. The lawsuit alleges that Microvast made materially false and misleading statements regarding margin targets, inventory management, and delays in the Huzhou Phase 3.2 expansion. The lead plaintiff deadline is September 21, 2026. Similar class action notices are being issued for PROCEPT BioRobotics and TransMedics Group.GlobeNewswire Inc. · Aug 9, 2026

TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDXRosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. The firm is seeking shareholders who currently own TMDX stock to join the investigation.GlobeNewswire Inc. · Aug 9, 2026

Why TransMedics Stock Is Sinking TodayTransMedics stock fell 8% after Q2 earnings showed 21% sales growth but adjusted net income dropped more than 50% due to reinvestment in new kidney organ care systems and manufacturing. Despite the decline, the analyst remains bullish on the stock, citing upcoming clinical trials for heart and lung systems, a new kidney OCS in development, and European expansion opportunities.The Motley Fool · Aug 5, 2026

Atlas Healthcare Fund by VST Capital Entered Eli Lilly at $350 in 2020 — The Stock Now Trades Above $1,200Atlas Healthcare Fund, managed by VST Capital, showcased its track record of early conviction investments in healthcare, with notable positions in Eli Lilly (entered at $350, now trading above $1,200), Alnylam Pharmaceuticals, TransMedics Group, and Inari Medical. The fund has delivered cumulative net returns of +1,720.9% since inception in January 2020, averaging over 57% annually, by identifying clinically differentiated technologies before mainstream market recognition.GlobeNewswire Inc. · Jul 17, 2026

Where Will TransMedics Group Stock Be in 10 Years?TransMedics Group is building a vertically integrated logistics network for organ transplantation through its Organ Care System (OCS) and National OCS Program, which extends organ viability during transport. Despite a 45% stock decline following Q1 2026 earnings miss due to margin compression from expansion spending, the company's 21% YoY revenue growth and potential kidney program expansion into Europe position it as a category-defining infrastructure provider in transplant medicine over the next decade.The Motley Fool · Jul 3, 2026

3 Growth Stocks to Buy on the DipThe article recommends three growth stocks experiencing temporary pullbacks: SoFi Technologies (down 34% YTD despite strong financial results), Robinhood Markets (facing crypto revenue headwinds but diversifying revenue streams), and TransMedics Group (expanding internationally with rising expenses but solid business fundamentals). All three are positioned as long-term opportunities for investors comfortable with volatility.The Motley Fool · Jul 2, 2026

What a $722,000 TransMedics Insider Sale Might Mean After a 45% Stock DropTransMedics Group director Thomas J. Gunderson sold 9,624 shares worth approximately $722,000 following the exercise of vested stock options to cover exercise costs and tax obligations. The sale reflects routine portfolio management rather than a loss of confidence. Despite a 45% stock decline over the past year, TransMedics reported strong Q1 revenue of $173.9 million (up 21% YoY) and maintained full-year guidance of $727-$757 million, suggesting the stock decline may have been an overreaction.The Motley Fool · Jun 24, 2026

TM

TMDXTransMedics Group, Inc. Common Stock

TMDX

Pay with—

Available Balance0.00

Your PositionYou don't own any TMDX yet.

Related Tickers

Earnings